The new VSS-GP saliva-based COVID-19 lateral flow test from Intelligent Fingerprinting makes testing far easier for all ages:
The Intelligent Fingerprinting VSS-GP test uses lateral flow technology to detect the SARS-CoV-2 antigen using a saliva sample.
Test results are available in 20 minutes – a third quicker than most current nose and throat lateral flow tests.
Unlike existing COVID-19 tests that require unpleasant, invasive nose and throat swabs, our test uses a simple swab to collect a saliva sample just from the inside of the cheek.
The test strip is deliberately simple in design and engineered to keep plastic usage to a minimum – with none of the plastic casing that is usually associated with lateral flow tests.
Because it is so easy to collect a saliva sample, the test is particularly suitable for use with more vulnerable people and children. It facilitates frequent testing across a range of applications including schools, workplaces, public events, care homes, healthcare, airports and prisons.
The test comprises a four-part kit with 50 single-use COPAN CE-marked swabs for saliva collection, 50 single-use plastic collection tubes with lids, and 50 single-use VSS-GP SARS-CoV2 test strips, along with a dropper bottle containing the reagent buffer.
The swab is used to collect the saliva sample from the inside of the lower cheek, which is then mixed with a reagent buffer that has been pre-added to the collection tube in order to release the virus. The screening test is performed by inserting the tip of the Intelligent Fingerprinting VSS-GP test strip into the sample, providing a positive or negative result at 20 minutes. No instrumentation is required.
Our test uses gold immunonanoparticle technology to enable the visual detection of bound antigen via a control line and a red line on the test strip when a saliva sample is positive for the SARS-CoV-2 Antigen.
Through independent evaluation, Intelligent Fingerprinting’s VSS-GP lateral flow saliva test has demonstrated 100% sensitivity in testing 150 positive clinical samples (Ct range 18.0 to 28.0), and 100% specificity following tests with 250 RT-PCR confirmed negative clinical saliva samples.
We are finalising the Technical File for applying the CE mark on this product under the In Vitro Diagnostics Directive, while also planning to transition to the In Vitro Diagnostics Regulation for European CE marking for professional and self-test use.
Manufacturing capacity at our Cambridge plant, utilising existing equipment and ISO 13485 quality control, is ready to support the production of millions of tests per month, and we also anticipate we will be working with existing and new distribution partners to make this test available across multiple markets.
Please get in touch for further information about products or partnership opportunities.